Circulating tumor DNA (ctDNA) testing is widely used in oncology to identify genomic
alterations. Our featured experts review the strengths and limitations of ctDNA testing in non …

Circulating tumor DNA (ctDNA) shed from cancer cells into the peripheral blood can be non-
invasively collected and tested for the presence of tumor-specific mutations. Mutations …

Circulating tumor DNA (ctDNA) consists of short, double-stranded DNA fragments that are
released into the circulation by tumor cells. With the advent of newer molecular platforms …

Circulating tumor DNA (ctDNA) has contributed immensely to the management of
hematologic malignancy and is now considered a valuable detection tool for solid tumors …

Opinion statement Isolation and analysis of circulating tumor DNA (ctDNA) have emerged as
an effective and promising tool for genomic profiling in non-small cell lung cancer. Analysis …

Lung cancer is the leading cause of cancer-related deaths worldwide, including Norway.
This study focused on non-small cell lung cancer (NSCLC), the most common subtype, and …

Highlights•Serial circulating tumor DNA profiling is emerging as biomarker to guide
treatment and monitor the disease.•In metastatic disease, liquid multigene assays have …

Purpose: Circulating tumor DNA (ctDNA) testing has become a promising tool to guide first-
line (1L) targeted treatment for advanced non-small cell lung cancer (aNSCLC). This study …

Circulating tumor DNA (ctDNA) detection has multiple promising applications in oncology,
but the road toward implementation in clinical practice is unclear. We aimed to support the …

The spatial and temporal genomic heterogeneity of various tumor types and advances in
technology have stimulated the development of circulating tumor DNA (ctDNA) genotyping …